The Filing Desk

IM Cannabis vs Lexicon Pharmaceuticals

IM Cannabis IMCC · Lexicon Pharmaceuticals LXRX · Pharmaceuticals

IM Cannabis reported revenue of C$55 million in fiscal 2025, and Lexicon Pharmaceuticals $50 million in fiscal 2025, in different currencies. IM Cannabis' revenue grew 1.3% in its latest year, and Lexicon Pharmaceuticals' grew 60.2%. IM Cannabis had an operating margin of -21.2%, against -98.2% at Lexicon Pharmaceuticals. Free cash flow was C$5 million at IM Cannabis and −$68 million at Lexicon Pharmaceuticals.

Side by side

IM CannabisLexicon Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
RevenueC$55M$50M
Revenue growth1.3%60.2%
Revenue growth a year, last 5 years28.0%15.7%
Gross margin17.7%99.5%
Operating margin−21.2%−98.2%
Net margin−20.7%−101.1%
Free cash flowC$5M−$68M
Free cash flow margin8.6%−136.2%
Return on capital−64.9%−105.0%
Net debt to EBITDA——
Dividends and buybacksC$0M$0M
Change in diluted share count—13.4%
Last close$0.47$1.67
P/E at the last close——
Insider trades, last 12 months—bought $2.7 million, sold $0
Piotroski F-score—4 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
IM CannabisLexicon Pharmaceuticals
Operating margin
Percent of revenue
IM CannabisLexicon Pharmaceuticals
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
IM CannabisLexicon Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the IM Cannabis and Lexicon Pharmaceuticals pages.